Detective Nephron: Poem Style

 Here is the next detective nephron but a poetic version

https://www.kidneynews.org/view/journals/kidney-news/18/4/article-p12_8.xml

KDIGO updates another IgAN guideline- 2026

 

Since the 2025 IgA nephropathy (IgAN) guideline update, three major therapies have reshaped the treatment landscape. Atrasentan, an endothelin A receptor antagonist, received accelerated approval for patients at high risk of progression (uPCR ≥1.5 g/g) based on the ALIGN trial. Added on top of RAS inhibition, it achieved a 38.1% reduction in proteinuria versus 3.1% with placebo, a significant 36.1% treatment difference.

Later in 2025, sibeprenlimab, an anti-APRIL monoclonal antibody targeting B-cell–mediated IgA production, was approved following the VISIONARY trial. It demonstrated a 50.2% reduction in proteinuria versus a 2.1% increase with placebo (difference 51.2%). Importantly, it also showed robust biologic effects, reducing pathogenic Gd-IgA1 by ~70% along with significant reductions in total IgA, IgM, and IgG.

Most recently, iptacopan, a complement factor B inhibitor, showed strong long-term outcomes. Over two years, it significantly slowed eGFR decline and reduced kidney failure events (HR 0.57), with an overall safety profile similar to placebo, though with higher rates of serious infections.

Together, these therapies target distinct pathways—hemodynamic, immunologic, and complement—marking a new era of mechanism-driven IgAN treatment.

Here is the most recent KDIGO update
Above cartoon was created using AI for illustrating a battle of the new class of agents for IgAN treatment

Perspective : Not All AKI in Cancer Is ATN: A Diagnostic Wake-Up Call

AKI is increasingly common in patients with cancer. Between sepsis, volume depletion, contrast exposure, and nephrotoxic therapies, it is often tempting—and convenient—to attribute kidney injury to acute tubular necrosis. 

But what if we are wrong more often than we think?

The Problem: Diagnostic Anchoring in Onconephrology

Cancer patients represent one of the most complex populations we manage. They are exposed to multiple therapies, experience rapid physiologic changes, and frequently have overlapping clinical syndromes. Despite this, many cases of AKI are still labeled as “ATN” early in the course, often without further evaluation. This diagnostic anchoring creates a critical blind spot—one that risks missing treatable and potentially reversible causes of kidney injury.

What Are We Missing?

Several important entities can mimic ATN in patients with cancer:

Immune checkpoint inhibitor–associated acute interstitial nephritis (AIN):
With the widespread use of PD-1, PD-L1, and CTLA-4 inhibitors, AIN is increasingly recognized. It is often delayed in onset, subtle in presentation, and highly responsive to corticosteroids. Without biopsy, it is frequently missed.

Thrombotic microangiopathy (TMA):
TMA can occur in association with VEGF inhibitors, hematologic malignancies, transplantation, and even cancer itself. Importantly, it may present without classic hematologic features. Complement-mediated mechanisms are increasingly implicated. Renal limited TMA is so common and often gets missed due to lack of heme parameters. 

Light chain–mediated kidney disease:
Cast nephropathy, light chain deposition disease, and other monoclonal protein–related injuries are not always immediately recognized, particularly outside specialized hematologic settings. Often this is missed in the setting of lymphoma and NON plasma cell based heme cancers. 

Drug-induced tubulointerstitial injury:
Proton pump inhibitors, antibiotics, and targeted cancer therapies can all contribute to kidney injury. These often coexist with immunotherapy, further complicating the clinical picture.

Non Dilated Obstruction:

This is definitely missed. We see this in Onconephrology all the time and especially in retroperitoneal mets cancers and or RP masses. Renal sonogram will show NO hydronephrosis but it is still hydronephrosis and b/l PCNs improve the renal function. 

Why This Matters

Multiple studies comparing clinical diagnoses with kidney biopsy findings have demonstrated significant discordance. A substantial proportion of cases initially presumed to be ATN are reclassified after biopsy—many into diagnoses that would change management.

Despite this, kidney biopsy is often deferred due to concerns about procedural risk, patient acuity, or the perception that it will not alter treatment decisions. Increasingly, however, that assumption does not hold true.

A Practical Framework: When to Pause and Reconsider

Before assigning a diagnosis of ATN in a patient with cancer, it is worth pausing and asking whether the full differential has been considered.

Red flags that should prompt further evaluation include:

• Recent or ongoing immunotherapy

• Exposure to VEGF inhibitors or novel targeted agents ( often most folks don't do a good detailed oncology history of meds)

• Underlying or suspected hematologic malignancy

• Lack of kidney recovery despite supportive care

• Presence of proteinuria or active urine sediment

Key questions to consider:

• Would identifying AIN change management (e.g., initiation of steroids)?

• Could this represent TMA requiring targeted or complement-directed therapy?

• Would a kidney biopsy meaningfully guide treatment decisions?

• Would this patient benefit from PCN as clinically seems to have hydronephrosis but no signs on imaging?

In this setting, labeling AKI as “ATN” without careful consideration is no longer sufficient.

AKI in patients with cancer is often more than just ATN. It may reflect immune-mediated injury, complement dysregulation, or monoclonal protein–related disease.

Recognizing these possibilities is essential to delivering the right treatment at the right time.

How often are you performing kidney biopsies in patients with cancer and AKI?
Have biopsy findings changed your management in unexpected ways?
Are we underutilizing kidney biopsy in this population?

Concept Map: APOL1 Mediated Kidney Disease (AMKD)

 

Consult Rounds: the Heart Failure, hyponatremia and no clues on physical exam???-- Detective Nephron style

The Heart Failure That Left No Clues on Physical Exam

Patient: Severe heart failure

Exam: Shockingly normal
Question: Where did the signs go?

CLUE #1: The Missing Congestion

• No crackles

• No JVD

• No edema

What may be happening?
Chronic HF adapts. Lymphatics drain. Veins stretch. Congestion hides.

CLUE #2: The Resting Alibi

• Looks fine in bed

• Symptoms only with exertion

What really is happening?
The exam interrogates patients at rest—CHF commits its crimes on exertion.

CLUE #3: Masked by Modern Therapy

• Diuretics

• ARNI / MRA

• SGLT2 inhibitors

What is possible?
Congestion is controlled. The disease is not.

CLUE #4: The Low-Output Plot Twist

• Poor perfusion

• Fatigue, weakness

• No obvious volume overload

This is Low-output HF leaves few visible footprints.

CLUE #5: Body Habitus Interference

• Obesity

• Thick chest wall

Strange: Classic signs are present—but physically undetectable.

What a nephrologist can do to get FORENSIC EVIDENCE 

What solves the case when the exam fails:

• Echocardiography -- looking also at IVC

• BNP / NT-proBNP

• Lung ultrasound (B-lines > crackles)

• Hemodynamics when needed ( RHC)

Severe heart failure with a silent physical exam

Verdict: The bedside exam detects overt congestion, not chronic compensation or low-output physiology. Use POCUS wisely!

HSCT -TA-TMA, the Kidney, and Complement-Targeted Therapies: Where We Are Now

Hematopoietic Stem Cell Transplant-associated thrombotic microangiopathy (TA-TMA) is a devastating complication of hematopoietic stem cell transplantation characterized by endothelial injury, microvascular thrombosis, and multiorgan dysfunction. The kidney is the most commonly and severely affected organ, with patients frequently developing acute kidney injury, proteinuria, hypertension, and long-term CKD. Renal involvement strongly predicts poor survival.

A figure from a recent review summarizes the challenges we have to diagnose TA-TMA and the limited treatment options of steroids, rituximab, and maybe eculizumab in certain cases.

Mounting evidence implicates complement dysregulation, particularly beyond the terminal C5 pathway, in TA-TMA pathogenesis. The strongest clinical data to date support narsoplimab, a monoclonal antibody targeting MASP-2 in the lectin pathway. Across multiple expanded-access and real-world case series—including the largest global cohort—narsoplimab demonstrated markedly improved 1-year survival in both adults and children, many with baseline renal dysfunction. Outcomes were best when used early, and safety signals were acceptable. These data culminated in FDA approval in December 2025 for TA-TMA in adults and children ≥2 years.

Beyond MASP-2 inhibition, upstream complement blockade is emerging. Iptacopan (factor B inhibitor) has been reported in small adult case series with improvement in hematologic markers and reduction in proteinuria, supporting a role for alternative pathway inhibition. Pegcetacoplan (C3 inhibitor) has been described in pediatric off-label cases and is under prospective investigation, reflecting interest in broader complement control for refractory disease.

Together, these studies suggest that earlier, upstream complement inhibition may provide better protection for the renal microvasculature and improve outcomes in TA-TMA compared with C5-only strategies.

HTN and TMA- Topic Discussion

Malignant hypertension with AKI or AKD is a life-threatening emergency that demands rapid blood-pressure control and carries a high risk of permanent kidney damage. When thrombotic microangiopathy (TMA) is present, diagnostic challenges intensify. Although complement-mediated TMA frequently presents with severe hypertension, malignant hypertension itself can cause TMA-like vascular injury. This has been a point of debate for many years. Does the TMA cause HTN or is HTN a cause of TMA as well? 

Early evaluation must therefore exclude secondary hypertension and secondary TMAs, which require etiology-specific treatment. Because a definitive distinction between essential hypertension and complement-mediated TMA relies on genetic testing that takes weeks, clinicians must use clinical and histologic clues to guide early complement-blocker therapy. Significant gaps remain in understanding pathogenesis, diagnosis, and treatment. A recent paper in KI really takes this to a better understanding. 

Some key messages from the review article

1. Malignant hypertension can directly cause a true TMA.
Severely elevated blood pressure can injure small vessels, leading to endothelial damage, platelet consumption, hemolysis, and classic TMA findings. This is not simply “secondary hemolysis”—it is a bona fide microangiopathic process.
2. Distinguishing hypertensive TMA from other TMAs is critical.
Hypertensive TMA can mimic HUS/TTP and complement-mediated TMA. Misdiagnosis can delay the correct therapy. The clinical context (markedly high BP, long-standing HTN, LVH, retinal changes) is key.
3. Treatment hinges on rapid but careful blood-pressure control.
The cornerstone is controlled BP reduction—typically in the ICU—with parenteral antihypertensives. This alone often reverses hematologic abnormalities and improves renal function.
4. ADAMTS13 and complement studies help guide management but should not slow treatment.
Work-up is important, especially when features are atypical or improvement is slower than expected. But initial management should start immediately based on clinical suspicion.
5. Kidney recovery varies widely—follow-up matters.
Some patients experience near-complete recovery; others progress to CKD or ESRD, especially when treatment is delayed. Long-term blood-pressure control is essential to prevent recurrence and preserve renal function.

     An important component is the heme component of TMA and it's presence in the systemic form of TMA. The figure( similar to the paper in KI) suggests that the complement-mediated TMA had most likely to have heme parameters of TMA as well followed by drug induced TMA and systemic diseases.  HTN is not that common.